Quantification of Dopamine Transporter by 123I-PE2I SPECT and the Noninvasive Logan Graphical Method in Parkinsons Disease
Caroline Prunier, MD1,
Pierre Payoux, MD2,
Denis Guilloteau, PhD1,
Sylvie Chalon, PhD1,
Bruno Giraudeau, PhD3,
Cynthia Majorel, PhD2,
Mathieu Tafani, PhD2,
Erwan Bezard, PhD4,
Jean-Paul Esquerré, PhD2 and
Jean-Louis Baulieu, PhD1
1 Nuclear Medicine Department, Institut National de la Santé et de la Recherche Médicale Unit 316, Bretonneau Hospital, Tours, France
2 Nuclear Medicine Department Équipe dAccueil 3033, Purpan Hospital, Toulouse, France
3 Clinical Research Center, François Rabelais University, Tours, France
4 Basal Gang, Laboratoire de Neurophysiologie, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5543, Victor Segalen University, Bordeaux, France

View larger version (50K):
[in a new window]
|
FIGURE 1. 123I-PE2I SPECT (acquisition between 35 and 50 min after injection) of healthy volunteer and 4 PD patients according to 4 stages of Hoehn and Yahr clinical score. All PD patients are characterized by progressive reductions in dopamine nigrostriatal terminal density, first in putamen and then in caudate nucleus.
|
|

View larger version (16K):
[in a new window]
|
FIGURE 2. Kinetics of 123I-PE2I in striatum (caudate nucleus and putamen) and occipital lobe in healthy volunteer (A) and parkinsonian patient (B) according to 4 sequential SPECT acquisitions. (C) Quantification of distribution volume of 123I-PE2I in striatum according to slope of Logan plot in healthy volunteers and parkinsonian patients.
|
|
Copyright © 2003 by the Society of Nuclear Medicine.